Facebook
X
LinkedIn
Forward
Advancing Patient-Centered Care in Narcolepsy Type 1: Integrating the Latest Evidence, Guidelines, and Treatment Innovations
Pricing: Free for Members and Non-Members
Course Description
For people living with narcolepsy type 1, getting the right diagnosis and accessing effective treatment can be a long road, often lasting many years. As new therapies targeting novel pathways move closer to availability, managed care has an opportunity to rethink how we support these patients, with coverage design and shared decision-making. This session puts the patient perspective front and center. We'll explore what individuals with narcolepsy need from their care, how emerging treatment options may address gaps left by current therapies, and how payers can support efforts to improve access and outcomes.
This activity is supported by an independent educational grant from Takeda Pharmaceuticals, U.S.A., Inc.
Target Audience
Pharmacists who practice in managed care settings.
Learning Objectives
At the completion of this activity, participants should be able to:
- Explain the latest diagnostic criteria and evidence-based guidelines for narcolepsy type 1, incorporating both objective findings and patient-reported experiences into managed care strategies.
- Review current and emerging therapeutic options for narcolepsy type 1, including orexin-targeted treatments, in terms of efficacy, safety, mechanism of action, and ability to meet unmet patient needs.
- Examine the patient’s journey and perspective of the lived experience with narcolepsy type 1 on treatment value, shared decision-making, and access to care.
- Discuss the impact of soon-to-emerge narcolepsy type 1 therapies and evolving guidelines on clinical practice, focusing on how these advances may reshape patient expectations, access, and health outcomes.
Shelby Cole, RN, BSN
Patient Advocate
Wake Up Narcolepsy
Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA
Founder & CEO
LoneStar Health Solutions
Luis E. Ortiz, MD
Assistant Professor of Pediatrics
Johns Hopkins School of Medicine
Disclosures:
| Faculty/Reviewer/Planner | Reported Relevant Financial Relationships |
| Shelby Cole Faculty | Disclosed no relevant financial relationships |
| Amy Lugo Faculty | Disclosed no relevant financial relationships |
| Luis Ortiz Faculty | Advisor: Alkermes, Avadel, Harmony Biosciences, Jazz Pharmaceuticals; Individual Stocks/Stock Options: Ascendis, AstraZeneca, Moderna, Pfizer; Faculty/Speaker: Takeda |
| Drake Reiter Peer Reviewer | Advisor and/or Consultant: Avalon Healthcare Solutions, BioMedical Insights, Capyision, COES, Comprehensive Care Sustainability Collaborative, Eversana, GLG, Havas, Haleh Institutes Research Center (HIRC), Impact Education, MMIT, SUN Pharma |
| Jennifer L. Evans Planner | Disclosed no relevant financial relationships |
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE UAN: 0233-0000-26-019-H04-P • Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: April 20, 2026 • Expiration Date: December 31, 2027
Activity Fee: Free for Members and Non-Members
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2026. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
Available Credit
- 1.25 ACPEThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.